Triumvira Immunologics
Business Services · Texas, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
9433 Fm 2244 Rd Bldg I Ste 240, Austin, ...Phone Number
(512) 790-0222Website
www.triumvira.comRevenue
$24 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Triumvira Immunologics
Triumvira Immunologics, Inc. ("Triumvira") is a clinical stage immunotherapy company with the vision of developing novel T cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and functions independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are in Austin, Texas, with our research facilities in Hamilton, Ontario.Explore more
Triumvira Immunologics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Triumvira Immunologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Triumvira Immunologics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Triumvira Immunologics had a recent Job posting/layoffs
Earning: See what the market has to say on Triumvira Immunologics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Triumvira Immunologics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Triumvira Immunologics
Funding: Get notified immidiatlly once Triumvira Immunologics has new funding data
Check out if Triumvira Immunologics is spiking on competitors!
Product Launch: Get notified when Triumvira Immunologics launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Triumvira Immunologics
Compare insights from companies similar to Triumvira Immunologics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Triumvira Immunologics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Triumvira Immunologics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Triumvira Immunologics.
Triumvira Immunologics financials insights
Gather financial insights about Triumvira Immunologics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$100M
Triumvira Immunologics Tech Stack
A closer look at the technologies used by Triumvira Immunologics
See more technologies
Most Recent Scoops
Person-Based
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Promotion
Executive Move
New Hire
Executive Move
Triumvira Immunologics News & Media
Triumvira Immunologics Presents Updated Clinical Data at the 2025 ASCO Gastrointestinal Cancers Symposium
AUSTIN, Texas and HAMILTON, ON and SAN DIEGO, Jan. 27, 2025 /PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, recently...Triumvira Immunologics' Late-Breaking Abstract Selected for Oral Presentation at the 39th SITC Annual Meeting Demonstrates Preliminary Safety and Promising Clinical Activity of TAC01-CLDN18.2 Cell Therapy in Patients with Solid Tumors
TAC01-CLDN18.2 was well tolerated, with no dose-limiting toxicities and a favorable safety profile in the first two cohorts of the ongoing trial A pancreatic cancer patient treated with the lowest dose has demonstrated clinical benefit for nearly eight months and achieved a confirmed...Triumvira Immunologics Announces Publication Demonstrating the Safety and Efficacy of TAC T Cells Targeting Claudin 18.2 in Solid Tumors
SAN DIEGO and AUSTIN, Texas and HAMILTON, ON, Oct. 15, 2024 /PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today...Triumvira Immunologics Announces First Patient Dosed in Phase I/II Cell Therapy Trial of TAC101-CLDN18.2 for the Treatment of Claudin 18.2+ Solid Tumors
SAN DIEGO and AUSTIN, Texas and HAMILTON, ON, Feb. 5, 2024 /PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Triumvira Immunologics
Sign Up For FreeTo access detailed company insights
Triumvira Immunologics, Inc. ("Triumvira") is a clinical stage immunotherapy company with the vision of developing novel T cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (T... Read More
